During our first conversation in the spring of 2012, Gilman said that he would go public unless he received assurances that CPRIT would retain its integrity after his departure.
Greg Simon, executive director of the cancer moonshot task force, addressed the FDA-sponsored workshop for Accelerating Anticancer Agent Development and Validation in North Bethesda, Md., May 4.
The White House moonshot to accelerate progress in cancer research directs FDA to consolidate its oncology portfolio.
FDA granted Orphan Drug Designation to VAL-083 in the treatment of ovarian cancer. The investigational drug candidate, developed by DelMar Pharmaceuticals Inc., previously received an orphan designation for glioma and medulloblastoma in the United States and glioma in Europe. In more than 40 phase I and II clinical studies sponsored by NCI, VAL-083 demonstrated clinical […]
FDA approved Cabometyx (cabozantinib) tablets for the treatment of patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy.
ABBVIE will acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T) currently in registrational trials for small cell lung cancer. The transaction is expected to close in second-quarter of this year. Rova-T is a novel biomarker-specific therapy that is derived from cancer stem cells and targets delta-like protein 3 that is expressed in more […]
GEISINGER HEALTH SYSTEM announced that 100,000 recruits have signed up for the health system’s major biobank and DNA sequencing study known as the MyCode Community Health Initiative. Launched in January 2014 in collaboration with the Regeneron Genetics Center, the MyCode Community Health Initiative originally set out to recruit 100,000 study participants. That target, however, was […]
THE INDIANA UNIVERSITY Melvin and Bren Simon Cancer Center raised nearly $1.2 million for cancer research at its fourth annual Chuckstrong Tailgate Gala. Hosted by the Indianapolis Colts and head coach Chuck Pagano at the Indiana Farm Bureau Football Center, the gala raised the funds through corporate sponsorships, live and silent auctions, and the annual […]
ABBVIE and argenx, a clinical-stage biopharmaceutical company, will collaborate to develop and commercialize ARGX-115, Argenx’s preclinical-stage human antibody program targeting the immuno-oncology target GARP, a protein believed to contribute to immuno-suppressive effects of T-cells. “ARGX-115 has been developed in collaboration with an outstanding team of academics at the de Duve Institute / Université Catholique de […]
THE WISTAR INSTITUTE and Cormorant Pharmaceuticals AB, a Swedish biopharmaceutical company specializing in cancer drug development, formed a partnership involving Cormorant’s novel drug HuMax-IL8, which is undergoing a phase I trial at NCI. “Wistar’s biomarker analysis of the tumor samples will be instrumental in determining the effects of HuMax-IL8 on tumor immunosuppression,” said Maarten de […]
